Balyasny Asset Management
ARIA

Balyasny Asset Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Balyasny Asset Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-285,566
Closed -$471K – 1587
2016
Q3 		$471K Buy
+285,566
New +$2.87M ﹤0.01% 751

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Balyasny Asset Management's ARIA Position: Q4 2015 in Review

Balyasny Asset Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2015, closing a stake of 14,760 shares — an estimated $86K sold.

Balyasny Asset Management first reported a position in ARIA in Q1 2015 and held it in 3 quarters. The position peaked at $12.6M in Q2 2015. 172 funds tracked by Wall St. Rank hold ARIA as of Q4 2015.

  • Balyasny Asset Management reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Balyasny Asset Management sold 14,760 Ariad Pharmaceuticals Inc shares in Q4 2015, an estimated $86K.
  • Balyasny Asset Management first reported a position in Ariad Pharmaceuticals Inc in Q1 2015 and held it in 3 quarters.
  • Balyasny Asset Management's Ariad Pharmaceuticals Inc position peaked at $12.6M in Q2 2015.
  • 172 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2015.

Based on Balyasny Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.